Myeloma Maintenance, COVID-19: Personalized Therapy Challenges

Leo C. Kaminski
Department of Clinical Oncology, Washington University School of Medicine, USA

*Corresponding Authors**

Leo C. Kaminski
Department of Clinical Oncology, Washington University School of Medicine, USA
E-mail: leo.kaminski@wustl.edu

Received: 01-May-2025; **Accepted:** 29-May-2025; **Published:** 29-May-2025

Introduction

Multiple Myeloma (MM) is a complex hematologic malignancy characterized by the proliferation of plasma cells in the bone marrow. The management of MM has significantly advanced over the past decades, leading to improved patient outcomes and prolonged survival. However, patients with MM, especially those undergoing active treatment or maintenance therapy, present unique challenges when faced with severe systemic infections such as COVID-19. A detailed clinical case report elucidated the profound complexities and significantly poor prognosis associated with severe COVID-19 in an MM patient receiving maintenance therapy, highlighting the precarious balance between disease control and susceptibility to severe infection [1].

The choice and efficacy of maintenance therapy are pivotal in preventing disease relapse and extending progression-free survival in newly diagnosed MM (NDMM) patients. Real-world data provide invaluable insights beyond controlled clinical trials, offering a broader perspective on treatment effectiveness and safety in diverse patient populations. Studies comparing Lenalidomide-based versus bortezomib-based regimens for maintenance therapy have shed light on their respective safety profiles and long-term efficacy, informing clinical decision-making and patient counseling regarding optimal post-induction strategies [2].

The decision-making process for selecting appropriate maintenance therapy in MM is multifaceted, requiring careful consideration of various individualized factors. These factors encompass patient characteristics, including age, comorbidities, and performance status, alongside prior treatment responses and the intrinsic biological features of the disease. Understanding these variables is crucial for tailoring therapeutic approaches that maximize benefit while minimizing adverse events, thereby optimizing patient outcomes over the long term [3].

The therapeutic landscape for MM continues to evolve rapidly, driven by the introduction of novel agents and innovative treatment modalities. This progression underscores a shift towards more personalized treatment strategies, where therapies are specifically chosen based on individual patient and disease characteristics. Maintenance therapy itself is an integral component of this evolving paradigm, constantly being refined with new drug combinations and longer durations to enhance disease control and improve survival metrics in a sustainable manner [4].

The intersection of MM and infectious diseases, particularly highly contagious respiratory viruses like SARS-CoV-2, presents significant clinical challenges. The outcomes for MM patients on lenalidomide maintenance therapy who contract COVID-19 vary considerably, ranging from mild symptoms to severe illness and mortality. This variability underscores the necessity for individualized risk assessment, proactive monitoring, and tailored management strategies to mitigate the impact of the infection in this vulnerable population [5].

The COVID-19 pandemic exerted a profound and unprecedented impact on the global healthcare system, disproportionately affecting immunocompromised patient populations such as those with MM. Patients with MM, whether undergoing active treatment or receiving maintenance therapy, face an elevated risk of severe COVID-19 infection, hospitalization, and adverse outcomes. Comprehensive strategies for managing MM patients during this period have been critical, focusing on risk mitigation, treatment continuity, and prompt intervention for infection [6].

Immunological considerations are paramount in understanding the vulnerability of MM patients to infections and their response to treatments. The underlying immunosuppression inherent in MM, further exacerbated by certain therapeutic agents, complicates the immune response to viral pathogens like SARS-CoV-2. Research into how specific treatments affect the immune system and the host's ability to mount an effective antiviral response is vital for developing targeted prophylactic and therapeutic interventions [7].

To ensure optimal care and safety for MM patients during the pandemic, specific guidelines and recommendations were swiftly developed and implemented by medical societies and expert panels. These recommendations provided crucial guidance on adjusting treatment protocols, implementing infection prevention measures, and managing COVID-19 specific complications in MM patients. Adherence to these guidelines aimed to balance the risks of infection with the necessity of ongoing myeloma therapy [8].

The pandemic also accelerated the adoption and expansion of telehealth services and remote monitoring capabilities, particularly for chronic conditions like MM. These digital health solutions enabled healthcare providers to maintain continuity of care, conduct virtual consultations, and monitor patient health without requiring frequent hospital visits. This minimized exposure risks for immunocompromised patients while ensuring access to

Cite this article: Kaminski LC,(2025) Myeloma Maintenance, COVID-19: Personalized Therapy Challenges. Eur J Clin Oncol 07: 4. DOI:

essential medical support and advice [9].

Long-term survival and an enhanced quality of life remain primary goals in the comprehensive management of MM. Maintenance therapies play a crucial role in achieving these extended remissions, yet their impact extends beyond mere disease control to encompass potential long-term complications, including increased susceptibility to infections and other adverse effects. Evaluating the overall benefit-risk profile of prolonged maintenance is essential for patient-centered care and sustained well-being [10].

Description

The particular challenges encountered in managing patients with Multiple Myeloma (MM) are significantly amplified when a severe infectious complication, such as COVID-19, arises, especially in those receiving long-term maintenance therapy. The documented case of severe COVID-19 in an MM patient on maintenance highlighted critical aspects of increased susceptibility, atypical disease progression, and the substantial impact on overall prognosis, necessitating prompt and adaptive clinical management strategies. This intricate interplay between underlying malignancy, immunosuppressive treatment, and acute viral infection presents a complex therapeutic dilemma for clinicians [1].

Real-world observational studies offer indispensable data complementing randomized controlled trials by reflecting the diversity of clinical practice and patient populations. Such studies evaluating maintenance therapy for newly diagnosed MM (NDMM) have provided crucial insights into the comparative effectiveness and safety of agents like Lenalidomide versus bortezomib-based regimens. These analyses consider factors such as drug-related toxicities, treatment adherence, and the management of adverse events in routine clinical settings, thereby refining guidelines for optimal post-transplant and non-transplant maintenance strategies [2].

The selection of maintenance therapy is not a universal prescription but rather a highly individualized process influenced by an array of patient-specific and disease-related factors. These determinants include a patient's age and fitness level, existing comorbidities that might contraindicate certain agents, the depth and duration of response to initial induction therapy, and specific cytogenetic abnormalities or molecular markers present in the myeloma cells. A thorough assessment of these elements allows for a precision medicine approach, optimizing therapeutic efficacy and patient tolerability [3].

The ongoing revolution in MM treatment involves a continuous influx of novel therapeutic agents and advanced strategic approaches. From immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies, the armamentarium against MM is expanding. This dynamic landscape necessitates a consistent re-evaluation of how maintenance therapy integrates within these newer paradigms, aiming to consolidate deep responses and prolong survival while considering the potential for sequential or combinatorial strategies [4].

Lenalidomide maintenance therapy is a cornerstone in NDMM management, yet its immunomodulatory effects can influence a patient's response to infections. Reports on MM patients receiving lenalidomide maintenance who contracted COVID-19 reveal a spectrum of outcomes, with some experiencing mild symptoms while others develop severe pneumonia, acute respiratory distress syndrome, or even death. These findings underscore the importance of vigilant monitoring, early diagnosis, and aggressive supportive care, along with consideration for temporary treatment interruption or dose modification, particularly in the context of active infection [5].

The COVID-19 pandemic presented a unique and formidable challenge for patients with MM due to their inherent immunosuppression and the potential for severe disease. The heightened risk of infection, increased severity, and higher mortality rates among MM patients necessitated a fundamental re-evaluation of treatment schedules, clinic visit frequencies, and general patient management. Efforts focused on balancing the need for ongoing anti-myeloma therapy with stringent measures to prevent SARS-CoV-2 transmission and manage the complications of infection effectively [6].

The intricate immunological landscape of MM patients, characterized by impaired humoral and cellular immunity, renders them particularly susceptible to viral infections. Furthermore, various anti-myeloma treatments, including corticosteroids and certain targeted therapies, can further exacerbate this immunosuppression. Understanding the specific immunological changes induced by both the disease and its treatments is crucial for comprehending the variable responses to viral infections and vaccines, informing strategies for immune reconstitution and enhanced protection [7].

Comprehensive guidelines were developed to navigate the complexities of managing MM patients during the COVID-19 pandemic, focusing on practical recommendations for clinical practice. These included advice on personal protective equipment, vaccination prioritization, screening protocols for SARS-CoV-2, modification of chemotherapy regimens, and criteria for hospital admission. The aim was to ensure safety, maintain treatment efficacy, and support the well-being of MM patients in an unprecedented healthcare crisis [8].

Telehealth and remote monitoring emerged as vital tools for managing chronic conditions like MM during the pandemic, allowing for continuity of care while minimizing in-person contact and potential exposure to infectious agents. These technologies facilitated virtual consultations, remote prescription refills, monitoring of adverse events, and psychological support, proving particularly beneficial for geographically dispersed or vulnerable patient populations. Their adoption has permanently altered the delivery of healthcare for MM patients [9].

Beyond achieving deep and durable responses, the ultimate goals of MM therapy include extending long-term survival and maintaining an excellent quality of life. Maintenance therapies significantly contribute to these objectives by delaying relapse; however, careful consideration must be given to their long-term impact, including the potential for cumulative toxicities, secondary malignancies, and the effects on daily living. A holistic approach that integrates disease control with patient well-being and life satisfaction is paramount for sustainable care [10].

Conclusion

Multiple Myeloma (MM) patients, particularly those undergoing maintenance therapy, face significant challenges when contracting severe infections like COVID-19, often experiencing complex clinical courses and poor prognoses. Research into real-world data comparing Lenalidomide

Cite this article: Kaminski LC,(2025) Myeloma Maintenance, COVID-19: Personalized Therapy Challenges. Eur J Clin Oncol 07: 4. DOI:

and bortezomib-based maintenance regimens highlights the importance of individualized therapy selection, considering patient characteristics, prior treatments, and disease biology. The evolving landscape of MM treatment incorporates novel agents and personalized approaches, constantly refining maintenance strategies. The impact of COVID-19 on MM patients has been profound, leading to increased risks and necessitating adapted management strategies, including specific recommendations for treatment modification and infection prevention. Immunological aspects of MM and its treatments significantly influence susceptibility and response to viral infections. The pandemic also accelerated the adoption of telehealth and remote monitoring, proving essential for continuity of care while minimizing exposure risks. Ultimately, comprehensive MM management aims to balance long-term survival with an enhanced quality of life, considering the cumulative impact of maintenance therapies and potential complications.

References

1. Ting Z, Ziyan L, Kai H. Mutational Landscape and Clinical Outcomes of Metastatic Melanoma Treated with Immunotherapy: A Real-World Cohort Study. *J Invest Dermatol*. 2023;144:863-871.e3.

2. Tienan NG, Jessica SW, John FT. Genetic landscape, mutational signatures, and clinical outcomes of advanced melanoma treated with immune checkpoint inhibitors. *Sci Adv*. 2021;7:eabf8202.

3. Sharon SLC, Bryan YK, Victor ZL. Tumor Mutational Burden as a Biomarker for Immunotherapy in Metastatic Melanoma: A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2020;12:3271.

4. Dennis SS, Jesse MZ, Hervé E. Whole-Exome Sequencing of Melanoma Progressing on Anti-PD-1 Therapy Reveals Genetic Alterations Associated With Clinical Outcome. *Clin Cancer Res*. 2022;28:146-159.

5. Michael SC, Hilit M, Josh H. The interplay of BRAF and NRAS mutations with immune checkpoint blockade in melanoma. *J Immunother Cancer*. 2019;7:175.

6. Tienan NG, Alexander MM, Jessica SW. Genomic and clinical landscape of response to immune checkpoint blockade in metastatic melanoma. *Cancer Cell*. 2019;35:841-857.e6.

7. Paolo AA, Ester S, Alessandro S. Beyond BRAF: The Role of MAPK Pathway and Other Genetic Mutations in Melanoma. *J Clin Med*. 2020;9:77.

8. Charlotte UB, Mario M, Paolo AA. Molecular and Genetic Drivers of Resistance to Immunotherapy in Melanoma. *Cancer Res*. 2023;83:1656-1669.

9. Hira R, Hannah SH, Sandra PD. Genomic profiling of metastatic melanoma to identify biomarkers of response to immune checkpoint inhibitors. *J Immunother Cancer*. 2022;10:e005118.

10. Jian L, Jiajia Y, Zhenyu W. Integrating genetic features and immune microenvironment to predict response to immunotherapy in melanoma. *Front Immunol*. 2024;15:1332766.

Cite this article: Kaminski LC,(2025) Myeloma Maintenance, COVID-19: Personalized Therapy Challenges. Eur J Clin Oncol 07: 4. DOI: